News

Bayer Finds Pulmonary Embolism Patients Are Not Adequately Screened for PH

Representatives from Bayer HealthCare Pharmaceuticals presented findings at the American Thoracic Society’s (ATS) 2015 International Conference that suggest pulmonary hypertension is more prevalent in patients with pulmonary embolisms than was previously thought. Although the rate may be at least twice as high as previously identified, many patients do not undergo the…

Celsion Corporation Announces TheraSilence Technology Effective in Model of Potential Severe Occlusive PAH Treatment

Celsion Corporation, an oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies, recently announced an abstract publication in the Journal of Controlled Release. The abstract summarizes results from a preclinical trial which confirmed the effective…

Mitral Valve Surgery Identified As Potential Treatment For PAH Secondary to Mitral Valve Disease

In a recent study entitled “An excellent result of surgical treatment in patients with severe pulmonary arterial hypertension following mitral valve disease,” authors analyzed recent outcomes and mortality rates for patients with pulmonary arterial hypertension who underwent mitral valve surgery. They observed a significant decrease in the number of deaths…

Actelion Presents Phase III Clinical Data at ATS Conference

Representatives from Actelion Pharmaceuticals Ltd will be presenting data from its Phase III GRIPHON and SERAPHIN studies at the American Thoracic Society (ATS) Conference 2015, held in Denver, Colorado. GRIPHON focused on the investigational drug selexipag (Uptravi®), while SERAPHIN focused on macitentan (Opsumit®). Both were used for patients with pulmonary…

Bellerophon Therapeutics Creates PH-Focused Scientific Advisory Board For INOpulse Programs

Bellerophon Therapeutics, Inc., a clinical-stage biotherapeutics company, recently announced the formation of a Scientific Advisory Board (SAB) for its INOpulse technology that includes internationally recognized experts in the field of pulmonary hypertension (PH). The SAB will work closely with Bellerophon’s medical team while the firm prepares to further the advancement of its proprietary inhaled…

SteadyMed Seeks Orphan Drug Designation for PAH Drug

Specialty pharmaceutical company SteadyMed Ltd. has filled an application requesting orphan drug designation for its lead medical product, an investigational therapy to treat pulmonary arterial hypertension (PAH) called Trevyent. The application has been acknowledged by the U.S. Food and Drug Administration (FDA) and…

Team PHenomenal Hope Celebrates World PH Day

Tuesday, May 5th was World Pulmonary Hypertension Day, and to mark the occasion Team PHenomenal Hope, a cycling team comprised of medical and endurance professionals, shared with the PH community how to help raise awareness about pulmonary hypertension. Team PHenomenal Hope has been a highly effective advocate for the disease…

PHA Reveals Encouraging Results From National Call-In Day

The Pulmonary Hypertension Association (PHA) has shared the results of its recent National Call-In Day, reporting that the event was a major success thanks to the participation of the pulmonary hypertension community. The National Call-In Day took place on April 16th as part of an initiative to encourage PH advocates to call Congressional members and…